Lilly and IU School of Medicine Partner on Rotation Program for Medical Students
Through a partnership with Lilly USA, third- and fourth-year medical students from IU School of Medicine are learning about drug development and how the many physicians working at Lilly play different and important roles in bringing new and innovative medicines to patients.
Through a partnership with Lilly USA, third- and fourth-year medical students from IU School of Medicine are learning about drug development and how the many physicians working at Lilly play different and important roles in bringing new and innovative medicines to patients.
The Medical Student Rotation Program is a four-week experiential learning program. Through real-world projects and workshops, the students become directly involved with various departments within Lilly, such as research, clinical trial development, medical affairs, regulatory, bioethics, and patient safety. The rotation program is designed around a student-centric curriculum and is guided by experienced, knowledgeable mentors at Lilly who help students explore drug development and diverse career options in healthcare. Through these experiences, students learn about the pharmaceutical industry and its place in the practice of medicine.
Read the full release here.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
Phase III Trial Data Show Subcutaneous Pembrolizumab as Noninferior to IV Keytruda
March 31st 2025Subcutaneous administration of pembrolizumab with chemotherapy demonstrated a nearly 50% reduction in patient chair and treatment room time while maintaining efficacy and safety endpoints compared to intravenous Keytruda.
Phase II ALPACA Trial Shows Lepodisiran Produces Significant, Sustained Lipoprotein(a) Reductions
March 31st 2025Eli Lilly’s lepodisiran, an investigational siRNA therapy, achieved significant and durable reductions in lipoprotein(a) levels, a major genetic risk factor for cardiovascular disease.
